Generic Name

Ibandronate

FDA approval date: March 19, 2012
Classification: Bisphosphonate
Form: Injection, Tablet

What is Ibandronate?

Ibandronate sodium tablet is a bisphosphonate indicated for the treatment and prevention of postmenopausal osteoporosis.

Approved To Treat

Top Global Experts

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

Changes of Bone Turnover Markers and Bone Mineral Density After Treatment in Osteoporotic Patients
Changes of Bone Turnover Markers and Bone Mineral Density After Treatment in Osteoporotic Patients
Enrollment Status: Recruiting
Publish Date: September 21, 2021
Intervention Type: Device
Study Phase: Phase 4

Summary: To examine the changes of bone mineral density and bone turnover markers after Bonviva treatment in osteoporotic patients

View All Clinical Trials

Related Latest Advances

Association of Osteoporosis and Bone-Strengthening Medications with Postoperative Outcomes Following Transforaminal Lumbar Interbody Fusion.
Association of Osteoporosis and Bone-Strengthening Medications with Postoperative Outcomes Following Transforaminal Lumbar Interbody Fusion.
Journal: World neurosurgery
Published: September 15, 2025
Prescription Trends by Orthopedic Surgery Provider: Review of the Medicare Part D Prescribers - by Provider and Drug, 2013-2021.
Prescription Trends by Orthopedic Surgery Provider: Review of the Medicare Part D Prescribers - by Provider and Drug, 2013-2021.
Journal: Orthopedics
Published: August 11, 2025
Medication-related osteonecrosis of the jaw following osteoporosis therapy: A real-world retrospective cohort study using the TriNetX global collaborative network.
Medication-related osteonecrosis of the jaw following osteoporosis therapy: A real-world retrospective cohort study using the TriNetX global collaborative network.
Journal: Bone
Published: July 05, 2025
View All Latest Advances